What early clinical results did Lilly report for its JAK2 Type II inhibitor AJ1-11095?

At the 2026 European Hematology Association meeting, Eli Lilly unveiled first-in-human data showing AJ1-11095 achieved a 35% or greater spleen volume reduction in most myelofibrosis patients who had failed prior Type I JAK inhibitors. The strong efficacy and tolerability validate Lilly’s Ajax acquisition and position the candidate as a potential new option for resistant disease.